Oxemia (desidustat) / Zydus Lifesciences - LARVOL DELTA

Tumor vascularization of NSCLC depending on nocturnal hypoxemic stress (DGT 2026) - "There are no differences in tumor vascularization.However, hypoxemia was associated with a higher IC score in adenocarcinoma.The evaluation of the number of vessels proved to be technically simple.Computer-aided 3D analyzes should be used to make more reliable statements.In the future, other hypoxemia-associated markers (e.g. VEGF or caspase) should also be examined and correlated with clinical parameters such as perioperative course or response to therapy."

IO biomarker • Chronic Obstructive Pulmonary Disease • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • CD34 • PD-L1

A Phase IIa, Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease. (PubMed, Eur J Haematol) - "Desidustat was well tolerated, with the 150 mg dose showing promising improvements in hemoglobin levels and response rates in SCD patients."

Journal • P2a data • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Pain • Sickle Cell Disease

Zydus and ICMR successfully completed the Phase II Proof-of-concept (PoC) trial to evaluate the efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease (Firstwordpharma Press Release) - "The study met its primary endpoint, demonstrating positive outcomes in line with the trial objectives....The study found that Desidustat was well tolerated up to 150 mg dose, with only minimal adverse events reported. The trial demonstrated a promising trend toward improvement in Hb levels and higher responder rates compared to placebo in patients with SCD. Across the three dose (50 mg, 100 mg and 150 mg), the drug exhibited a favourable safety and tolerability profile. The incidence of treatmentemergent adverse events (TEAEs) was low and comparable across cohorts."

P2 data • Trial completion • Sickle Cell Disease

Zydus Lifesciences…has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease (Firstwordpharma Press Release) - "Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease."

New P3 trial • Anemia • Sickle Cell Disease

From Evidence to Practice with Desidustat/HIF-PHIs: Insights from the Indian Experience (ERA 2026) - "Supported by Zydus Lifesciences Limited."

Anemia • Chronic Kidney Disease • Hematological Disorders

ISS2.2: Leading the Shift in CKD Anemia Care: Spotlight on HIF-PHIs (ERA 2026) - "This has led to the development of HIF prolyl-hydroxylase inhibitors (HIF-PHIs), a novel class of agents that stimulate endogenous erythropoietin production, suppress hepcidin, enhance iron utilization, lower LDL-cholesterol, and offer the convenience of oral administration. Emerging evidence also points toward its potential utility in indications beyond CKD anemia. This symposium will provide a comprehensive review of the evolving role of HIF-PHIs—particularly Desidustat—in optimizing anemia management in CKD and ESRD, enriched with real-world insights from clinical practice across India."

Anemia • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

'Translating Trial Data to Practice: Real-World Impact of Desidustat in CKD" (ERA 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Chronic Kidney Disease

Synergistic Management of Anemia in Chronic Kidney Disease: Efficacy and Safety of Combined Desidustat and Low-Dose Erythropoietin Therapy (ERA 2026) - "The significant rise in Hb, coupled with the mobilization of iron stores without adverse incidents, suggests that this "dual-pathway" approach may allow for better glycemic and hypertensive management in anemic patients by potentially reducing the high-dose ESA burden. Image"

Clinical • Anemia • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease • Retinal Disorders

Two‑Year Real‑World Experience with Desidustat for Anemia in Chronic Kidney Disease: A Retrospective Analysis (ERA 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

OVERCOMING EPO HYPORESPONSIVENESS: IS DESIDUSTAT THE ANSWER? (ERA 2026) - No abstract available

Chronic Kidney Disease • Nephrology • Renal Disease

Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease. (PubMed, J Pak Med Assoc) - "Recent Kidney Disease: Improving Global Outcomes (KDIGO) anaemia guidelines acknowledge HIF-PHIs as therapeutic alternatives in selected patients. This review synthesizes available evidence and provides practical, evidence-based recommendations for the use of desidustat across different stages of CKD."

Journal • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation. (PubMed, Trials) - "Management of sickle cell disease (SCD) has limited treatment modalities available like hydroxyurea and blood transfusions. They offer benefits but their limitations underscore the ongoing need for safer, more effective, and accessible treatments. This proof-of-concept trial was conducted to investigate the efficacy and safety of desidustat oral tablet, 3 times per week for 8 weeks in SCD patients. Results from this trial could aid in establishing a cost-efficient therapeutic option for managing rare diseases like SCD."

Clinical • Journal • P2a data • Genetic Disorders • Hematological Disorders • Rare Diseases • Sickle Cell Disease

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on lipid profiles in patients with chronic kidney disease: a systematic review and meta-analysis. (PubMed, Eur J Clin Pharmacol) - "Roxadustat showed the most substantial lipid-lowering effects, while desidustat showed significant reductions in LDL-C and total cholesterol but no significant effects on triglycerides or HDL-C, and molidustat showed no significant effects. Despite these changes in lipid profiles, no significant differences in cardiovascular outcomes were observed for these three HIF-PHIs, compared with ESAs or placebo."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Hematological Disorders • Myocardial Infarction • Nephrology • Renal Disease

Desidustat's cardioprotective mechanisms in heart failure: a network pharmacology, molecular docking and dynamics approach. (PubMed, Sci Rep) - "This hypothesis-generating in silico study suggests that Desidustat acts via a polypharmacological mechanism, potentially modulating key metabolic and inflammatory pathways through central targets like HSP90AA1. These findings provide a mechanistic basis that warrants further experimental and preclinical investigation to evaluate Desidustat's non-hemodynamic cardioprotective potential as a complementary strategy in HF treatment."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Nephrology • Renal Disease • CDC37 • ER • HSP90AA1 • STAT3

Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study. (PubMed, Nephrology (Carlton)) - "Treatment with desidustat resulted in improvement in haemoglobin levels with acceptable tolerability over short-term follow-up similar to erythropoietin. The convenience of oral administration supports its potential role as a patient-centred option for anaemia management following kidney transplantation."

Biomarker • Clinical • Journal • Observational data • Anemia • Hematological Disorders • Transplantation

COMPARATIVE EVALUATION OF DESIDUSTAT VERSUS ERYTHROPOIETIN ON HEMOGLOBIN CORRECTION, IRON UTILISATION AND COST IN DIALYSIS-DEPENDENT CKD PATIENTS: A 12-MONTH RANDOMIZED CONTROLLED STUDY (ISN-WCN 2026) - "In the health-economic analysis across all dialysis schedules and dialyser types, the annual medication cost was ₹ 76,024 for the Desidustat group versus ₹ 84,840 for the EPO group, yielding an 11.6 % cost reduction though this difference did not reach statistical significance.Download: Download high-res image (203KB)Download: Download full-size imageConclusion Desidustat demonstrated superior hemoglobin correction, better iron utilisation and lower annual treatment cost compared to Erythropoietin, with comparable safety in DD-CKD. The oral HIF-PHD inhibitor thus represents an effective, patient-convenient, and economically favourable alternative to injectable ESA therapy for renal anemia management in real-world Indian settings."

Clinical • Cardiovascular • Chronic Kidney Disease • Hypertension • Mental Retardation • Musculoskeletal Pain • Nephrology

REDEFINING ANEMIA TREATMENT IN CKD: A DUAL-MODALITY STRATEGY WITH ESA AND HIF-PHIS (ISN-WCN 2026) - "No serious adverse events or treatment-related discontinuations; except in 2 patients where dose of anti-hypertensives was scrolled up.Download: Download high-res image (64KB)Download: Download full-size imageConclusion Desidustat add-on therapy produced a statistically significant and sustained rise in Hb among CKD patients inadequately responding to ESAs, with corresponding improvement in iron utilization. The therapy was well tolerated and effective across dialysis and non-dialysis groups, underscoring Desidustat's role as a valuable adjunct and potential maintenance option in CKD-related anemia."

Anemia • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology

A RANDOMIZED PROSPECTIVE STUDY COMPARING DESIDUSTAT AND ERYTHROPOIETIN FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON PERITONEAL DIALYSIS(CAPD). (ISN-WCN 2026) - "Its oral route, favorable biomarker profile, and renal safety position Desidustat as a promising, next-generation alternative for anemia management in dialysis-dependent CKD. Further multicenter validation is warranted."

Clinical • Anemia • Chronic Kidney Disease • Hematological Disorders • Inflammation • Nephrology • Renal Disease • CRP

A PHASE-4, 52-WEEK, SINGLE ARM, POST-MARKETING SURVEILLANCE TO EVALUATE SAFETY OF DESIDUSTAT FOR TREATMENT OF ANEMIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (ISN-WCN 2026) - "In terms of efficacy, treatment with Desidustat led to an increase in hemoglobin level, a reduction in serum hepcidin, and no significant change in VEGF and e-GFR levels.Conclusion This ongoing, phase 4 study demonstrated a favorable safety profile and sustained efficacy over 24 weeks in the treatment of anemia in patients with chronic kidney disease, irrespective of dialysis status. These interim findings support long-term use of Desidustat as a safe and effective oral HIF-PHI for managing anemia in CKD patients."

Clinical • P4 data • Anemia • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease • Thrombocytopenia

EFFICACY OF DESIDUSTAT IN ERYTHROPOIETIN-HYPORESPONSIVE CKD PATIENTS: A REAL-WORLD EVALUATION AS PER KDIGO GUIDELINES (ISN-WCN 2026) - "Statistical comparisons were performed using paired t-tests.Results At baseline, mean Hb was 7.07 ± 0.52 g/dL.Following switch to Desidustat:Hb at 1 month: 7.83 ± 0.63 g/dL (Δ = +0.76 g/dL; +10.7%, p = 0.00023)Hb at 3 months: 8.55 ± 0.71 g/dL (Δ = +1.48 g/dL; +20.9%, p = 0.00052)Despite previous high-dose EPO exposure with suboptimal response, patients demonstrated a clinically and statistically significant rise in Hb within 3 months of Desidustat therapy.Download: Download high-res image (69KB)Download: Download full-size imageMetabolic parameters remained stable throughout follow-up:Creatinine: 3.25 ± 1.00 mg/dLCalcium: 8.92 ± 0.36 mg/dLPhosphate: 4.62 ± 0.60 mg/dLALP: 118.8 ± 33.97 U/LNa/K: 138.5 ± 2.88 / 4.57 ± 0.39 mmol/LTransferrin Saturation: 27.47 ± 6.83%Ferritin: 288.8 ± 99.24 ng/mLNo significant derangements or safety concerns were observed, suggesting a favorable tolerability profile.Conclusion Desidustat..."

Clinical • HEOR • Real-world • Real-world evidence • Chronic Kidney Disease • Hematological Disorders • Nephrology

Real World Evidence with Desidustat: India's Contribution to the Global HIF Story (ISN-WCN 2026) - "Organized By: Zydus LifeSciences"

Clinical • HEOR • Real-world • Real-world evidence • Anemia • Chronic Kidney Disease • Hematological Disorders

Industry Symposium 43: Reimagining Anemia Management in CKD: Evolution with HIF-PHIsTheme: Preserving Kidney Health (ISN-WCN 2026) - "Newer evidence also suggests a possible role of this new class of drugs beyond anemiaThis symposium reviews the evolving role of CKD anemia management in the era of HIF PHIs with Real-World Experience from India. Learning Objectives:Understand how HIF-PHIs work and why treatment is shifting from ESAs to HIF-PHIs.Review key clinical and real-world evidence for Desidustat and other HIF-PHIs.Apply practical guidance on patient selection, initiation, and monitoring for Desidustat/HIF-PHIs"

Anemia • Chronic Kidney Disease • Hematological Disorders

CMS(867.HK/8A8.SG): New Drug for Renal Anaemia Desidustat Tablets Approved in China (The Manila Times) - "The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients...Its China Phase III clinical trial has demonstrated positive results."

China approval • Anemia • Chronic Kidney Disease • Renal Disease

A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. (PubMed, Am J Nephrol) - "Desidustat significantly improved Hb levels and accelerated anemia correction in NDD-CKD patients versus placebo, with comparable safety."

Clinical • Journal • P3 data • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Zydus secures Orphan drug designation for sickle cell therapy in US (The Economic Times) - "Desidustat, marketed under the brand name ‘Oxemia’, helps in boosting red blood cell production."

Orphan drug • Sickle Cell Disease